

# FDG-PET Imaging for Lymph Node Staging and Pathologic Tumor Response after Neoadjuvant Treatment of Non-small Cell Lung Cancer

Takashi Ohtsuka, MD,<sup>1</sup> Hiroaki Nomori, MD,<sup>1</sup> Akinori Ebihara, MD,<sup>2</sup> Ken-ichi Watanabe, MD,<sup>1</sup> Masahiro Kaji, MD,<sup>1</sup> Tsuguo Naruke, MD,<sup>1</sup> Keiichi Suemasu, MD,<sup>1</sup> and Kimiichi Uno, MD<sup>3</sup>

**Purpose:** A number of studies have demonstrated that <sup>18</sup>F-fluorodeoxyglucose positron emission tomography (FDG-PET) is effective for staging of lung cancer. However, the efficacy of FDG-PET for staging lung cancer after neoadjuvant treatment is still controversial. This study compared FDG-PET and computed tomography (CT) for lung cancer staging, and evaluated the ability of the two methods to predict the pathologic response of the primary tumor to neoadjuvant treatment.

**Patients and Methods:** Twenty-two patients who underwent neoadjuvant treatment followed by surgery were investigated. Eighteen patients received chemoradiotherapy and four patients received chemotherapy only. One hundred and three lymph node stations in the 22 patients were evaluated by FDG-PET and CT. The pathologic responses of the tumors were compared by FDG-uptake and tumor size on CT for the 15 patients who underwent FDG-PET and CT both before and after neoadjuvant treatment.

**Results:** There was no significant difference in the ability of FDG-PET or CT to predict residual viable tumor. Although positive predictive value by FDG-PET (0.29) was lower than that by CT (0.64) ( $p=0.04$ ) in the mediastinal lymph nodes, there were no statistically significant differences in the other results of lymph nodes by FDG-PET and CT. Both decrease in FDG-uptake and decrease in tumor size by CT after neoadjuvant treatment correlated significantly with pathologic response in the 15 patients ( $p=0.003$  and  $0.009$ , respectively).

**Conclusion:** FDG-PET did not appear to offer any advantages over CT for lymph node staging or for predicting the pathologic response after neoadjuvant treatment of non-small cell lung cancer. (*Ann Thorac Cardiovasc Surg* 2006; 12: 89-94)

**Key words:** lung cancer, positron emission tomography, neoadjuvant treatment, pathologic response

## Introduction

It is generally accepted that multimodal therapy should be used for the treatment of locally advanced non-small

*From Departments of <sup>1</sup>Thoracic Surgery and <sup>2</sup>Internal Medicine, Saiseikai Central Hospital, and <sup>3</sup>Nishidai Clinic, Tokyo, Japan*

Received August 29, 2005; accepted for publication September 12, 2005.

Address reprint requests to Takashi Ohtsuka, MD: Department of Thoracic Surgery, Saiseikai Central Hospital, 1-4-17 Mita, Minato-ku, Tokyo 108-0073, Japan.

cell lung cancer. Neoadjuvant treatment followed by surgery is one type of multimodal therapy used for locally advanced non-small cell lung cancer.<sup>1)</sup> Several studies have demonstrated that <sup>18</sup>F-fluorodeoxyglucose positron emission tomography (FDG-PET) is effective for staging of lung cancer.<sup>2-5)</sup> However, the staging of lung cancer after neoadjuvant treatment remains difficult. This study was undertaken to evaluate the usefulness of FDG-PET for staging and predicting the pathologic tumor response to neoadjuvant treatment in 22 patients with non-small cell lung cancer, in comparison with the results of

Table 1. Characteristics of patients

Patient	Age	Sex	Histology	Neoadjuvant treatment	Pathologic stage	Effect
1	49	M	AD	C+R	T3N2	Partial response
2	52	M	SQ	C+R	T1N0	Partial response
3	36	M	AD	C+R	T2N0	Partial response
4	63	M	SQ	C+R	T1N0	Partial response
5	67	F	AD	C	T2N1	Partial response
6	70	M	SQ	C+R	T2N0	Partial response
7	74	M	SQ	C+R	T3N1	Partial response
8	64	M	SQ	C+R	T0N0	Partial response
9	65	M	SQ	C	T1N1	Partial response
10	64	M	AD	C+R	T1N3	Partial response
11	64	M	AD	C+R	T0N0	Partial response
12	63	M	SQ	C+R	T1N2	Partial response
13	59	F	AD	C+R	T2N1	No change
14	62	F	AD	C+R	T2N3	No change
15	53	M	AD	C+R	T1N1	No change
16	65	M	SQ	C	T1N2	No change
17	71	M	AD	C+R	T2N0	No change
18	68	F	AD	C	T2N1	No change
19	61	M	AD	C+R	T2N2	No change
20	66	M	AD	C+R	T4N2	No change
21	57	M	AD	C+R	T1N2	No change
22	65	M	AD	C+R	T2N2	No change

AD, adenocarcinoma; SQ, squamous cell carcinoma; C, chemotherapy; R, radiation therapy.

computed tomography (CT).

## Patients and Methods

Between December 2001 and September 2004, whole-body FDG-PET and CT scans of the chest were undertaken after induction treatment in 22 patients with biopsy-proven lung cancer. Of the 22 patients, 15 underwent FDG-PET and CT both before and after neoadjuvant treatment and the other seven patients underwent FDG-PET only after neoadjuvant treatment. The characteristics of the patients are shown in Table 1. There were 18 men and four women with a mean age of 61 years (range: 36-74 years). Preoperative chemotherapy was administered to all patients. Sixteen patients were administered carboplatin and vinorelbine, two were given carboplatin and docetaxel, two received carboplatin and paclitaxel, and one patient each received cisplatin and CPT-11, and carboplatin and gemcitabine. The mean number of courses was 2.3 (range: 1-6). Four patients received chemotherapy only, and 18 received both radiotherapy and chemotherapy. Seventeen patients received 30 Gy of chest irradiation and one patient received 60 Gy. The time interval between the end of neoadjuvant treatment and FDG-PET was a median of 1.6 months (range: 1-11 months). All

patients underwent pulmonary resection and systematic thoracic lymph node dissection. The lymph node stations were classified according to the original lymph node map of lung cancer.<sup>6)</sup> The pathologic diagnosis of 103 lymph node stations (N1=24, N2=72, N3=7) in the 22 patients was compared by lymph node staging with FDG-PET and CT.

## FDG-PET scanning and data analysis

Patients were instructed to fast for at least 4 hr prior to intravenous (IV) administration of <sup>18</sup>F-FDG. The administered dosage of <sup>18</sup>F-FDG was 125  $\mu$ Ci/kg (4.6 MBq/kg) body weight for non-diabetic patients and 150  $\mu$ Ci/kg (5.6 MBq/kg) body weight for diabetic patients. PET imaging was performed approximately 60 min after IV administration of FDG using a POSICAM.HZL mPOWER (Positron Corp., Houston, Texas, USA). No-attenuation-corrected emission scans were initially obtained in two-dimensional, high-sensitivity mode for 4 min per bed position, and taken from the skull to the thighs. Immediately thereafter, a two-bed-position attenuation-corrected examination was performed, with 6 min for the emission sequence and 6 min for the transmission sequence at each bed position. The images were usually reconstructed in a 256 $\times$ 256 matrix using ordered subset

expectation maximization corresponding to a pixel size of 4×4 mm, with section spacing of 2.66 mm.

PET data were evaluated semiquantitatively on the basis of the contrast ratio (CR) obtained as reported previously. Briefly, the regions of interest (ROIs) were chosen in the nodules or lymph nodes and cerebellum. The highest activities in the tumor or lymph node ROI (T or L) and in the cerebellum ROI (C) were measured. The CR was calculated by T/C in each nodule or L/C in each lymph node as an index of FDG-uptake. The primary tumors or lymph nodes with a CR  $\geq 0.25$  were diagnosed as having a viable tumor as reported previously.<sup>7)</sup> The decrease in CR after neoadjuvant treatment was calculated using the following formula: CR after neoadjuvant treatment/CR before neoadjuvant treatment.

### CT scanning and CT data analysis

Spiral CT was performed using a ProSeed SA (General Electric Health care, Milwaukee, Wisconsin, USA). The entire thorax was scanned in 1-cm-thick sections with maximal inspiration. World Health Organization (WHO) response criteria were used for efficacy analysis of the tumor.<sup>8)</sup> The criterion of CT definition for suspected metastasis of the lymph node was a short-axis diameter of 1 cm or larger. The area of the tumor was calculated as the multiplication of the longest diameter and the shortest diameter. The decrease in tumor area on CT after neoadjuvant treatment was calculated using the following formula: tumor area after neoadjuvant treatment/tumor area before neoadjuvant treatment.

### Pathologic response

Pathologic response was defined according to the article of The Japan Lung Cancer Society.<sup>9)</sup> A major pathologic response was defined as a residual tumor less than one-third the size of the original tumor. A minor pathologic response was defined as residual tumor greater than or equal to one-third of the original tumor. The pathologic response was determined by comparing the ratios of FDG-uptake and tumor area on CT before and after neoadjuvant treatment in the 15 available patients.

### Statistical analysis

True positive (TP), true negative (TN), false positive (FP) and false negative (FN) results of PET for residual tumor and lymph nodes were compared with the results of pathologic diagnosis. Sensitivity was calculated as TP/TP+FN, specificity as TN/TN+FP, positive predictive values (PPV) as TP/TP+FP, negative predictive values (NPV) as TN/

**Table 2. FDG-PET, CT, and residual viable tumor cells in the primary site**

	Viable tumor cells	
	+	-
PET positive	16	2
PET negative	4	0
CT positive	20	2
CT negative	0	0

FDG-PET, <sup>18</sup>F-fluorodeoxyglucose positron emission tomography; CT, computed tomography.

TN+FN and accuracy as TP+TN/total. The differences between major pathologic response and minor pathologic response of the tumor by FDG-uptake and size on CT were examined by the Mann-Whitney *U* test. The data obtained by FDG-PET and CT were compared by the chi-squared test. The data were considered statistically significant at  $p < 0.05$ . All values are expressed as the mean  $\pm$  SD.

## Results

### Detection of residual viable tumor at the primary site

While the effects of neoadjuvant treatment determined by CT were partial response in 12 and no change in 10 (Table 1), pathologic examination of the resected tumor showed that there were no viable cells in two patients. The results of the correlation between FDG-PET, CT and viable tumor cells are shown in Table 2. There were 16 patients with TP, four with FN and two with FP results by FDG-PET, 20 patients with TP and two patients with FP results by CT. There were no significant differences in the results of FDG-PET and CT.

### Lymph node staging with PET and CT

A comparison of clinical (after neoadjuvant treatment) and pathologic lymph node status determined by FDG-PET and CT is shown in Table 3. FDG-PET and CT accurately predicted nodal status in 11 (50%) and 10 patients (45%), respectively. A comparison of clinical and pathologic node status in N1, N2 and N3 stations determined by FDG-PET and CT is shown in Table 4. Sensitivity, specificity, PPV, NPV and accuracy of FDG-PET and CT are summarized in Tables 5 and 6. PPV by FDG-PET (0.29) was significantly lower than that by CT (0.64) ( $p=0.04$ ) in the N2 lymph node stations. However, there were no significant differences in the other results of FDG-PET and CT.

**Table 3. Comparison of clinical and pathological nodal status by FDG-PET and CT**

PET	Pathological nodal status			
	N0	N1	N2	N3
N0	5	2	2	0
N1	0	1	1	0
N2	2	3	4	1
N3	0	0	0	1

CT	Pathological nodal status			
	N0	N1	N2	N3
N0	5	2	2	0
N1	0	1	1	0
N2	2	3	4	2
N3	0	0	0	0

FDG-PET, <sup>18</sup>F-fluorodeoxyglucose positron emission tomography; CT, computed tomography.

**Table 4. Comparisons between clinical and pathologic nodal status with FDG-PET and CT**

		Lymph node metastasis	
		+	-
N1 station (n=24)	PET positive	4	5
	PET negative	1	14
	CT positive	2	1
	CT negative	3	18
N2 station (n=72)	PET positive	8	20
	PET negative	6	38
	CT positive	7	4
	CT negative	7	54
N3 station (n=7)	PET positive	2	0
	PET negative	2	3
	CT positive	0	0
	CT negative	4	3

FDG-PET, <sup>18</sup>F-fluorodeoxyglucose positron emission tomography; CT, computed tomography.

**Table 5. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy for lymph node staging by FDG-PET after neoadjuvant treatment**

Test	N1 lymph nodes	N2 lymph nodes	N3 lymph nodes	All lymph nodes
Sensitivity	0.80	0.57	0.50	0.61
Specificity	0.74	0.66	1.00	0.69
PPV	0.44	0.29	1.00	0.36
NPV	0.93	0.86	0.60	0.86
Accuracy	0.75	0.64	0.71	0.67

PPV, positive predictive value; NPV, negative predictive value; FDG-PET, <sup>18</sup>F-fluorodeoxyglucose positron emission tomography.

**Table 6. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy for lymph node staging by CT after neoadjuvant treatment**

Test	N1 lymph nodes	N2 lymph nodes	N3 lymph nodes	All lymph nodes
Sensitivity	0.40	0.50	0.00	0.39
Specificity	0.95	0.93	1.00	0.94
PPV	0.67	0.64	0.00	0.64
NPV	0.86	0.89	0.43	0.84
Accuracy	0.83	0.85	0.43	0.82

PPV, positive predictive value; NPV, negative predictive value; CT, computed tomography.

**Pathologic response**

In the 15 patients who underwent FDG-PET before and after neoadjuvant treatment, the ratios of FDG-uptake before and after neoadjuvant treatment in the major pathologic response patients (0.34±0.19) were significantly lower than those in the minor response patients (0.73±0.10)(p=0.003)(Fig. 1A). The ratios of tumor size

on CT before and after neoadjuvant treatment in the major pathologic response patients (0.39±0.15) were also significantly lower than those in the minor pathologic response group (0.78±0.25)(p=0.009) (Fig. 1B). There was no significant difference in the ability of FDG-uptake or tumor size on CT to predict pathologic response.




Fig. 1.

**A:** Distributions of the ratios of FDG-uptake in patients with a major and a minor pathologic response. The ratios of FDG-uptake in patients with a major pathologic response ( $0.34 \pm 0.19$ ) were significantly lower than those in the group with minor pathologic response ( $0.73 \pm 0.10$ ) ( $p=0.003$ ).

**B:** Distributions of the ratios of the size in patients with a major and a minor pathologic response. The ratios of tumor size in patients with a major pathologic response ( $0.39 \pm 0.15$ ) were also significantly lower than those in the group with minor pathologic response ( $0.78 \pm 0.25$ ) ( $p=0.009$ ).

## Discussion

Surgical resection has limited success in curing locally advanced non-small cell lung cancer. Recently, combined modality treatment for locally advanced non-small cell lung cancer has been performed.<sup>2)</sup> However, accurate staging of lung cancer is still difficult after neoadjuvant treatment.<sup>10-12)</sup> FDG-PET, which does not use the criterion of size, might be more accurate for detecting the actual presence of tumor in the lymph nodes than CT. In mediastinal lymph node staging of lung cancer without neoadjuvant treatment, sensitivity and specificity are reported to be 0.71-0.91 and 0.67-0.94, respectively.<sup>2-4,13)</sup> Several studies have shown good results for FDG-PET for the staging of lung cancer, even in patients who had received neoadjuvant treatment.<sup>14-16)</sup> Akhurst et al. reported that FDG-PET could accurately detect residual viable primary tumor,<sup>15)</sup> and Cerfolio et al. showed that FDG-PET had a higher PPV and NPV than CT for detecting residual tumor and paratracheal lymph nodes in patients who had received preoperative chemotherapy.<sup>16)</sup> On the other hand, Port et al. reported that FDG-PET did not accurately predict nodal stage after neoadjuvant treatment.<sup>17)</sup>

The current study showed that FDG-PET had a low PPV (0.29) when diagnosing mediastinal lymph nodes after neoadjuvant treatment. There were 20 FP lymph

nodes (28%) among the 72 N2 lymph nodes. This poor result is thought to be due to inflammatory lesions with invasion of macrophages and lymphocytes in the lymph nodes caused by chemotherapy or radiation therapy. These lesions may be responsible for the increased uptake of FDG and the FP findings reported previously.<sup>18)</sup>

Port et al. showed that FDG-PET did not reliably predict pathologic response to preoperative chemotherapy in non-small cell lung cancer.<sup>17)</sup> However, the current study demonstrates that the FDG-uptake of the primary tumor before and after neoadjuvant treatment was a good predictor of pathologic response of the tumor. We defined a major pathologic response as 'residual tumor less than one-third the size of the primary tumor'. According to this definition, FDG-uptake could reflect the pathologic response of the primary tumor.

Lymph node downstaging of locally advanced non-small cell lung cancer by neoadjuvant treatment correlates with long-term survival.<sup>19,20)</sup> FDG-PET did not offer any advantages over CT in the mediastinal lymph node and could not predict the lymph node downstaging of non-small cell lung cancer patients who received neoadjuvant treatment. Therefore, surgical intervention such as endoscopic biopsy or mediastinoscopy will be needed for accurate staging, since surgery after induction treatment is beneficial only in patients with pathologic downstaging.

## References

1. Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. *N Engl J Med* 1994; **330**: 153–8.
2. Dwamena BA, Sonnad SS, Angobaldo JO, Wahl RL. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s—meta-analytic comparison of PET and CT. *Radiology* 1999; **213**: 530–6.
3. Gupta NC, Tamim WJ, Graeber GG, Bishop HA, Hobbs GR. Mediastinal lymph node sampling following positron emission tomography with fluorodeoxyglucose imaging in lung cancer staging. *Chest* 2001; **120**: 521–7.
4. Albes JM, Dohmen BM, Schott U, Schulen E, Wehrmann M, Ziemer G. Value of positron emission tomography for lung cancer staging. *Eur J Surg Oncol* 2002; **28**: 55–62.
5. Nomori H, Watanabe K, Ohtsuka T, Naruke T, Suemasu K, Uno K. The size of metastatic foci and lymph nodes yielding false-negative and false-positive lymph node staging with positron emission tomography in patients with lung cancer. *J Thorac Cardiovasc Surg* 2004; **127**: 1087–92.
6. Naruke T, Suemasu K, Ishikawa S. Lymph node mapping and curability at various levels of metastasis in resected lung cancer. *J Thorac Cardiovasc Surg* 1978; **76**: 832–9.
7. Nomori H, Watanabe K, Ohtsuka T, Naruke T, Suemasu K, Uno K. Visual and semiquantitative analyses for F-18 fluorodeoxyglucose PET scanning in pulmonary nodules 1 cm to 3 cm in size. *Ann Thorac Surg* 2005; **79**: 984–9.
8. WHO Handbook for Reporting Results of Cancer Treatment. Geneva: WHO, 1979.
9. The Japan Lung Cancer Society. General Rules for Clinical and Pathologic Recording of Lung Cancer, 6th ed. Tokyo: Kanehara, 2003. (in Jpse.)
10. Lee KS, Shim YM, Han J, et al. Primary tumors and mediastinal lymph nodes after neoadjuvant concurrent chemoradiotherapy of lung cancer: serial CT findings with pathologic correlation. *J Comput Assist Tomogr* 2000; **24**: 35–40.
11. Mateu-Navarro M, Rami-Porta R, Bastus-Piulats R, Cirera-Nogueras L, Gonzalez-Pont G. Remediastinoscopy after induction chemotherapy in non-small cell lung cancer. *Ann Thorac Surg* 2000; **70**: 391–5.
12. Van Schil P, van der Schoot J, Poniewierski J, et al. Remediastinoscopy after neoadjuvant therapy for non-small cell lung cancer. *Lung Cancer* 2002; **37**: 281–5.
13. Hellwig D, Ukena D, Paulsen F, Bamberg M, Kirsch CM, Onko-PET der Deutschen Gesellschaft für Nuklearmedizin. [Meta-analysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose in lung tumors. Basis for discussion of the German Consensus Conference on PET in Oncology 2000]. *Pneumologie* 2001; **55**: 367–77.
14. Vansteenkiste JF, Stroobants SG, De Leyn PR, Dupont PJ, Verbeken EK. Potential use of FDG-PET scan after induction chemotherapy in surgically staged IIIA-N2 non-small-cell lung cancer: a prospective pilot study. The Leuven Lung Cancer Group. *Ann Oncol* 1998; **9**: 1193–8.
15. Akhurst T, Downey RJ, Ginsberg MS, et al. An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer. *Ann Thorac Surg* 2002; **73**: 259–66.
16. Cerfolio RJ, Ojha B, Mukherjee S, Pask AH, Bass CS, Katholi CR. Positron emission tomography scanning with 2-fluoro-2-deoxy-d-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma. *J Thorac Cardiovasc Surg* 2003; **125**: 938–44.
17. Port JL, Kent MS, Korst RJ, Keresztes R, Levin MA, Altorki NK. Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer. *Ann Thorac Surg* 2004; **77**: 254–9.
18. Ohtsuka T, Nomori H, Watanabe K, et al. False-positive findings on <sup>18</sup>F-FDG-PET caused by non-neoplastic cellular elements after neoadjuvant chemoradiotherapy for non-small cell lung cancer. *Jpn J Clin Oncol* 2005; **35**: 271–3.
19. Betticher DC, Hsu Schmitz SF, Totsch M, et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. *J Clin Oncol* 2003; **21**: 1752–9.
20. Trodella L, Granone P, Valente S, et al. Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA–IIIB) non-small-cell lung cancer: long-term results according to downstaging. *Ann Oncol* 2004; **15**: 389–98.

Original Articles

## [F-18]Fluorodeoxyglucose Positron Emission Tomography Can Predict Pathological Tumor Stage and Proliferative Activity Determined by Ki-67 in Clinical Stage IA Lung Adenocarcinomas

Ken-ichi Watanabe<sup>1</sup>, Hiroaki Nomori<sup>2</sup>, Takashi Ohtsuka<sup>1</sup>, Tsuguo Naruke<sup>1</sup>, Akinori Ebihara<sup>1</sup>, Hideki Orikasa<sup>3</sup>, Kazuto Yamazaki<sup>3</sup>, Kimiichi Uno<sup>4</sup>, Toshiaki Kobayashi<sup>5</sup> and Tomoyuki Goya<sup>6</sup>

<sup>1</sup>Department of Thoracic Surgery and Respiratory Group, Saiseikai Central Hospital, Tokyo, <sup>2</sup>Department of Thoracic Surgery, Graduate School of Medicine, Kumamoto University, Kumamoto, <sup>3</sup>Department of Pathology, Saiseikai Central Hospital, Tokyo, <sup>4</sup>Nishidai Clinic, Tokyo, <sup>5</sup>Development in Assistive Diagnostic Technology, National Cancer Center Hospital, Tokyo and <sup>6</sup>Department of Surgery, Kyorin University, Mitaka, Tokyo, Japan

Received December 18, 2005; accepted April 3, 2006; published online June 16, 2006

**Objective:** To predict a malignant grade of lung cancer by fluorodeoxyglucose positron emission tomography (FDG-PET) scanning, we investigated the correlation between FDG uptake and pathological tumor stage, proliferative activities determined by Ki-67 and cyclin D1, and an alteration of p53, in clinical stage (c-stage) IA lung adenocarcinomas.

**Methods:** FDG-PET was performed for 71 patients with c-stage IA lung adenocarcinomas. FDG uptake was measured by a contrast ratio (CR) between the tumor and contralateral lung. Ki-67, cyclin D1 and p53 staining scores were examined by immunohistochemistry.

**Results:** The lesions with ground-glass opacity were found in 26 patients, and solid lesions in 45 by computed tomography. The pathological tumor stages (p-stage) were stage IA in 59 and more advanced stages in 12. The latter had significantly higher CR value than the former ( $P < 0.001$ ). Patients with  $CR \geq 0.55$  could be predicted to be at advanced tumor stages, with a sensitivity of 0.83 and a specificity of 0.82. The CR and staining scores of Ki-67 were significantly correlated with each other ( $P < 0.0001$ ), and both the values were significantly higher in advanced tumor stages than in p-stage IA, and were also significantly higher in tumors with intratumoral lymphatic, vascular and pleural involvements than in those without such features ( $P < 0.05-0.0001$ ).

**Conclusions:** In c-stage IA lung adenocarcinomas, the FDG uptake can predict p-stage and tumor proliferative activity determined by Ki-67. For c-stage IA lung adenocarcinomas showing  $CR \geq 0.55$ , mediastinoscopy or neoadjuvant chemotherapy is indicated.

*Key words:* positron emission tomography – lung cancer – adenocarcinoma – tumor stage – proliferative activity – tumor suppressor gene

### INTRODUCTION

It has been reported that tumor proliferative activity and alterations of tumor suppressor genes could be prognostic factors in non-small cell lung cancer (NSCLC). Some authors have demonstrated that proliferative activities determined by Ki-67 (1) and cyclin D1 (2–5), and an alteration of p53 were

correlated with the prognosis of NSCLC patients (4,6,7). In recent years, F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) has been frequently used for the diagnosis and staging of lung cancer (8–10). FDG uptake has been reported to be correlated not only with the prognosis in NSCLC patients (11,12) but also with the proliferative activity (13,14) and alteration of p53 (7) of the tumor. However, we previously reported that the FDG uptake in NSCLC tumors was dependent on histological types, that is, FDG-uptake of adenocarcinomas correlated with the pathological tumor stage and tumor invasiveness, but that of the other histological types did not (15,16). Therefore, we consider that the correlation between the FDG

For all reprints and all correspondence: Hiroaki Nomori, Department of Thoracic Surgery, Graduate School of Medicine, Kumamoto University, 1-1-1, Honjo, Kumamoto 860-8556, Japan; E-mail: hnomori@kaiju.medic.kumamoto-u.ac.jp

uptake and the proliferative activity or alteration of p53 should be examined in adenocarcinomas, but not in NSCLC including all histological types. Furthermore, FDG uptake is known to be higher in larger tumors (17,18). Therefore, in the present study, we measured the FDG uptake in clinical stage IA adenocarcinomas and investigated its relationships with the pathological tumor stage, intratumoral invasiveness, proliferative activity determined by Ki-67 and cyclin D1 and the alteration of p53.

## PATIENTS AND METHODS

### PATIENTS

Between December 2001 and February 2005, FDG-PET was performed for 386 patients with pulmonary nodules. Of these, 301 patients had malignant tumors and 178 of the 301 patients had lung adenocarcinoma. Of the 178 adenocarcinoma patients, 77 were diagnosed as clinical stage IA by PET and thin section computed tomography (TSCT: <2 mm in thickness). They were treated by segmentectomy or lobectomy and lymph node dissection. Of these, we excluded six adenocarcinomas < 1 cm, because the spatial resolution of the PET scanner is 0.7–0.8 cm, making it difficult to image the pulmonary nodules that are <1 cm (16). Therefore, we studied 71 patients with clinical stage IA adenocarcinoma with a size range of 1–3 cm.

### FDG-PET SCANNING

Patients were instructed to fast for at least 4 h before intravenous (i.v.) administration of F-18 FDG. The dosage of F-18 FDG administered was 125  $\mu$ Ci/kg (4.6 MBq/kg) for non-diabetic patients and 150  $\mu$ Ci/kg (5.6 MBq/kg) for diabetic patients. PET imaging was performed ~60 min after administration of FDG with a POSICAM.HZL m-POWER (Positron Co., Houston, TX, USA). No attenuation-corrected emission scans were initially obtained in two-dimensional, high-sensitivity mode for 4 min per bed position, and taken from the vertical skull through the mid-thighs. Immediately thereafter, a two-bed-position attenuation-corrected examination was performed with 6 min for the emission sequence and 6 min for the transmission sequence at each bed position.

### PET IMAGE PROCESSING AND DATA ANALYSIS

The images were usually reconstructed in a 256  $\times$  256 matrix by using ordered subset expectation maximization corresponding to a pixel size of 4  $\times$  4 mm, with section spacing of 2.66 mm. FDG uptake was evaluated by contrast ratio (CR) with contralateral lung, as previously reported (15,16,19). Briefly, the regions of interest (ROI) were placed in the nodules and contralateral normal lung. Highest standardized uptake ratios in the tumor ROI (T) and in the contralateral lung ROI (N) were measured. The CR value was calculated by using the formula  $[(T - N)/(T + N)]$  in each nodule as an index of FDG uptake.

### PATHOLOGICAL ANALYSIS

Hematoxylin and eosin and Elastica-van Gieson stainings were performed in all sections to investigate the intratumoral lymphatic and vascular invasions and pleural involvement. Pleural involvement was classified as p0, p1, p2 and p3; that is, a p0 tumor did not extend beyond the pleural elastic layer; a p1 tumor invaded the visceral pleural elastic layer, but did not reach the pleural surface; a p2 tumor included tumor exposure on the pleural surface; and a p3 tumor invaded the parietal pleura or the chest wall. The tumor stages were based on the TNM classification of the International Union Against Cancer (20): p2 tumors were classified as T2, p3 tumors were classified as T3 and tumors with intrapulmonary metastases within the same lobe were classified as T4.

### PREDICTING ADVANCED TUMOR STAGES FROM FDG UPTAKE

Receiver operating characteristics (ROC) curve (21) was constructed according to the CR value, and the cut-off value was determined for predicting the pathological stages that were more advanced than stage IB.

### IMMUNOHISTOCHEMICAL ANALYSIS

Immunostaining was performed by using the Dako envision system (Dako Cytomation, Glostrup, Denmark). The antibodies for Ki-67 (monoclonal mouse antibody MIB-1, 1 : 100 dilution), cyclin D1 (monoclonal mouse antibody DCS-1, 1 : 50 dilution) and p53 (monoclonal mouse antibody, DO7, 1 : 400 dilution) were purchased from Dako Co. Sections of 4  $\mu$ m were cut from the paraffin blocks. Immunostaining was performed with antigen-retrieval techniques.

### EVALUATION OF IMMUNOHISTOCHEMICAL STAINING

#### *Ki-67*

According to the method of Martin et al. (1), the labeling index of Ki-67 was measured by determining the percentage of cells with positive nuclei in >1000 tumor cells in >4 fields.

#### *Cyclin D1 and p53*

The Allred score used to examine the staining scores of cyclin D1 as well as p53 was obtained by determining the percentage of positive tumor cells and staining intensity (22). Briefly, a percentage score was measured by determining the percentage of positive tumor cells in >1000 tumor cells in >4 fields (0, none; 1, <1/100; 2, 1/100–1/10; 3, 1/10–1/3; 4, 1/3–2/3; 5, >2/3). An intensity score was measured by the average of staining intensity (0, none; 1, weak; 2, intermediate; and 3, strong). The sum of the percentage score and the intensity score was used as the Allred score.

### STATISTICAL ANALYSIS

The values of CR and staining scores of Ki-67, cyclin D1 and p53 were compared between the pathological stage IA and the



Table 1. Patients' characteristics

Gender	
Male	45
Female	26
Age (years)	62 ± 10 (33–83)*
Size (mm)	19 ± 7 (10–30)*
CT findings	
GGO	26
Solid	45
Pathological stage	
IA	59
≥IB	12
T2N0M0	3
T1N1M0	4
T2N1M0	1
T1N2M0	1
T4N0M0	2
T4N2M0	1

\*Mean ± standard deviation (range), GGO: ground-glass opacity.

more advanced stages and between the two groups with or without intratumoral lymphatic, vascular invasion and pleural involvement, by the non-parametric Mann–Whitney's *U*-test. The correlations between the CR values and the staining scores of Ki-67, cyclin D1 and p53 were analyzed by using the non-parametric Spearman's rank test. All values in the text and tables are given as mean ± standard deviation.

**RESULTS**

Table 1 shows patients' characteristics. The lesion showing ground-glass opacity (GGO) image were found in 26 patients, and the solid lesions in 45 patients at visual TSCT findings. The pathological tumor stages were T1N0M0 in 59 patients and more advanced in 12 patients (i.e. T2N0M0 in 3, T1N1M0 in 4, T2N1M0 in 1, T1N2M0 in 1, T4N0M0 in 2 and T4N2M1 in 1).

Figure 1 shows the distribution of CR values in 59 patients with pathological stage IA and 12 patients with more advanced stages. The mean CR value of the 12 patients with advanced stages was 0.66 ± 0.12, which was significantly higher than 0.32 ± 0.18 of the 59 patients with pathological stage IA (*P* < 0.001).

Figure 2 depicts the ROC curve for predicting tumor stages more advanced than IB, showing the optimal CR cut-off value to be 0.55, of which sensitivity, specificity and accuracy were 0.83, 0.81 and 0.82, respectively. While 10 of the 12 patients (83%) with the advanced stage showed CR values ≥ 0.55, 48 of the 59 patients (81%) with pathological stage IA showed CR values < 0.55 (Table 2).




Figure 1. The distribution of CR values in the 59 patients with pathological stage IA and 12 patients with stages advanced more than IA. (CR = contrast ratio).




Figure 2. The ROC curve and CR values for predicting tumor stages more advanced than IA. (ROC = receiver operating characteristics; CR = contrast ratio).

Figures 3–5 show the distribution of staining scores of Ki-67, cyclin D1 and p53 in the 59 patients with pathological stage IA and 12 patients with more advanced stages. The mean score for Ki-67 in the 12 patients with advanced stages was 18.0 ± 11.0, which was significantly higher than 9.4 ± 12.0 for the 59 patients with pathological stage IA (*P* = 0.012). However, the mean scores for cyclin D1 in the advanced tumor stages and pathological stage IA were 3.9 ± 1.7 and 4.1 ± 1.8, respectively, of which difference was not significant. The mean scores for p53 in the advanced tumor stages and pathological stage IA were 3.3 ± 3.6 and 2.6 ± 2.6, respectively, of which difference was also not significant.

Table 2. Pathological tumor stage with the cut-off value of CR at 0.55

Pathological tumor stage	CR ≥ 0.55	CR < 0.55	Total
IA	11	48	59
≥IB	10	2	12
Total	21	50	71

≥IB: advanced stage more than IB.




Figure 3. The distribution of Ki-67 staining scores in the 59 patients with pathological stage IA and 12 patients with stages advanced more than IA.




Figure 4. The distribution of cyclin D1 staining scores in the 59 patients with pathological stage IA and 12 patients with stages advanced more than IA.

Table 3 shows the mean values of CR, Ki-67, cyclin D1 and p53 staining scores in tumors with or without intratumoral lymphatic, vascular and pleural involvements. Tumors with intratumoral lymphatic, vascular and pleural involvements had significantly higher values of both CR and Ki-67 staining scores ( $P < 0.05-0.001$ ). However, there were no significant differences of tumor invasiveness in the cyclin D1 and p53 staining scores.




Figure 5. The distribution of p53 staining scores in the 59 patients with pathological stage IA and 12 patients with stages advanced more than IA.

Table 4 shows the mean values of CR and Ki-67 staining scores in tumors with stage IA and advanced stages in tumors with GGO and solid images. In 26 tumors with GGO image, 25 were stage IA and the other one was stage IB. The GGO tumors showed significantly lower CR and Ki-67 staining scores than the solid tumors ( $P < 0.001$ ). The mean values of CR of the 25 GGO tumors with stage IA was  $0.17 \pm 0.14$ , while the CR of the one tumor with stage IB was 0.48. The mean values of Ki-67 staining scores of the 25 GGO tumors with stage IA was  $4.7 \pm 6.9$ , while the CR of the one tumor with stage IB was 0.16. In 45 tumors with solid image, 34 were stage IA and 11 were more advanced than stage IB. The mean values of CR of the 34 solid tumors with stage IA was  $0.43 \pm 0.20$ , which was significantly lower than  $0.67 \pm 0.11$  of the 11 tumors with more advanced stages ( $P < 0.001$ ). The mean values of Ki-67 staining scores of the 34 solid tumors with stage IA was  $13 \pm 13$ , which was lower than  $21 \pm 10$  of the 11 solid tumors with more advanced stages ( $P = 0.056$ ).

The CR value and Ki-67 staining scores were significantly correlated with each other ( $r = 0.42, P < 0.0001$ ) (Fig. 6). However, both cyclin D1 and p53 scores did not show any correlation with the CR values ( $r = 0.05$  and  $0.07$ , respectively).

## DISCUSSION

Although the standard uptake value (SUV) has been frequently used for evaluation of FDG-PET, it has been reported that several factors can affect the SUV, such as body size (23), blood glucose level (24), time after injection (25) and lesion size (17,18). In fact, the mean SUV of malignant pulmonary nodules has been reported to be various, ranging from 5.5 to 10.1 (26-29). We previously compared the results of SUV, CR with contralateral lung and CR with cerebellum for pulmonary nodules, and reported that the CR with contralateral lung or

**Table 3.** Correlation between intratumoral invasiveness and CR values and staining scores of Ki-67, cyclin D1 and p53

Invasiveness	Number of patients	CR	Ki-67	p53	Cyclin D1
ly (-)	38	0.29 ± 0.21	5.6 ± 8.1	2.2 ± 2.3	3.9 ± 1.8
(+)	33	0.48 ± 0.21*	17 ± 13*	3.4 ± 3.1	4.3 ± 1.8
v (-)	58	0.34 ± 0.23	9.9 ± 12	2.9 ± 2.7	4.1 ± 1.8
(+)	13	0.55 ± 0.20**	17 ± 12***	2.1 ± 3.0	3.8 ± 1.7
p 0	63	0.34 ± 0.20	9.7 ± 12	2.5 ± 2.6	4.1 ± 1.8
1-2	8	0.63 ± 0.13*	21 ± 8.3**	4.5 ± 3.6	3.8 ± 2.0

CR, contrast ratio; ly, lymphatic invasion; v, vascular invasion; p, pleural involvement.

\* $P < 0.001$ .

\*\* $P < 0.01$ .

\*\*\* $P < 0.05$ .


**Table 4.** The values of CR and Ki-67 of tumors with stage IA and advanced stages in tumors with solid and GGO images

Tumor findings and pathological stage	CR	Ki-67
GGO		
All cases ( $n = 26$ )	0.18 ± 0.14	4.5 ± 6.8
Stage IA ( $n = 25$ )	0.17 ± 0.14	4.7 ± 6.9
Stage IB ( $n = 1$ )	0.48	0.16
Solid		
All cases ( $n = 45$ )	0.48 ± 0.2*	15 ± 13*
Stage IA ( $n = 34$ )	0.43 ± 0.20	13 ± 13
≥Stage IB ( $n = 11$ )	0.67 ± 0.11†	21 ± 10

GGO, ground-glass opacity; CR, contrast ratio.

\*The differences of CR or Ki-67 staining scores between the GGO and solid lesions were  $P < 0.001$ .

†The difference of CR between the tumors with stage IA and ≥stage IB was  $P < 0.001$ .

**Figure 6.** The correlation between CR values and Ki-67 staining scores in the 71 patients with clinical stage IA.:  $r = 0.42$ ;  $P = 0.00043$ .

cerebellum showed significantly higher sensitivity than the SUV (19). We therefore used the CR value with contralateral lung in the present study.

The present study has demonstrated the following points: (i) tumors with high FDG uptake ( $CR \geq 0.55$ ) could be identified as those at stages that are more advanced than stage IB with the sensitivity of 0.83 and the specificity of 0.81; (ii) FDG uptake and Ki-67 staining scores correlated with the pathological tumor stage and intratumoral invasiveness,

although cyclin D1 and p53 did not show such correlation; and (iii) FDG uptake and Ki-67 scores were significantly correlated with each other.

Earlier reports have indicated that adenocarcinomas with GGO image are usually N0 stage and show low FDG uptake on PET (15,16,30). The present study is basically in agreement with these results, that is, adenocarcinomas with GGO image showed lower FDG uptake than those with solid one. However, one adenocarcinoma with GGO image was stage IB, which showed rather high CR than 25 stage IA tumors. In tumors with solid image, the 11 tumors with advanced stages showed significantly higher CR values than the 34 tumors with stage IA. Therefore, the FDG uptake on PET could be an independent factor for predicting pathological stage in clinical TINOM0 lung adenocarcinomas.

It has been reported that 25% of clinical stage IA adenocarcinomas are pathologically advanced tumor stage (31). Recently, neoadjuvant chemotherapy has been reported to improve survival in clinical stages IB, II and IIIA of NSCLC (32). The present study showed that the CR value of 0.55 could be the cut-off value for predicting advanced tumor stages more than IB. Therefore, we propose that to improve patients' prognosis in clinical stage IA adenocarcinoma, mediastinoscopy or neoadjuvant chemotherapy should be performed for clinical stage IA adenocarcinoma with  $CR \geq 0.55$ .

The Ki-67 antigen exists in the nucleus of proliferating cells and has been reported to be a prognostic factor in lung cancer (1). Vesselle et al. (14) reported that the FDG uptake correlated with Ki-67 staining scores in 39 patients with NSCLC. They also described that the correlation between the FDG-uptake and Ki-67 staining scores was stronger in stage I than in stages I-III. Their report supported the present study, showing a significant correlation between the FDG uptake and Ki-67 staining scores in clinical stage IA lung adenocarcinomas.

Cyclin D1 is known to regulate the  $G_1$ -to-S phase transition during the cell cycle, and its expression in tumor cells is reported to correlate with their proliferative activity. However, several immunohistochemical studies on involvement of cyclin D1 in lung cancer had shown different results (2-5). While some authors reported the opposite finding, that is, the cyclin D1 staining scores was a predictor of poor prognosis of NSCLC (4,5), others have questioned its role as a predictor (3).

On the other hand, another report described that the negative staining for cyclin D1 correlated with poor prognosis (2). While these previous studies examined the expression of cyclin D1 in NSCLC including all histological types, the present study investigated the clinical stage IA adenocarcinomas, showing that cyclin D1 scores did not correlate with the FDG uptake, pathological tumor stage or tumor invasiveness. Our results indicate that Ki-67 is a better marker for the proliferative activity and malignant grade of adenocarcinomas than cyclin D1.

An alteration of p53 is reported to be a poor prognostic factor in many types of tumors including lung cancer (6), although one recent report has denied it (2). While Sasaki et al. (7) reported that the FDG uptake in tumors with the alteration of p53 tended to be higher than in those without, the present study did not find any correlation of p53 staining scores with the FDG uptake, tumor stage and intratumoral invasiveness in clinical stage IA lung adenocarcinomas. The differences between the report by Sasaki et al. and ours were (i) the number of the patients (28 versus 71 patients); (ii) histological types (NSCLC including all histological types versus adenocarcinoma); (iii) size of tumors (17,18) (no details about specific sizes versus 1–3 cm); (iv) measurement of FDG uptake (SUV versus CR). As described in our previous reports, the FDG uptake should be measured by CR and not by SUV, and should also be evaluated in adenocarcinomas with limited tumor size (16,19). Therefore, we believe that the alteration of p53 does not correlate with FDG uptake and therefore cannot be a dictator for the malignant grade in clinical stage IA lung adenocarcinomas.

We conclude that the FDG uptake can predict pathological tumor stage and tumor proliferative activity determined by Ki-67, but cannot predict the alteration of p53 in clinical stage IA lung adenocarcinomas. These results should be useful in determining the indication for mediastinoscopy or neoadjuvant chemotherapy in patients with clinical stage IA lung adenocarcinoma.

### Acknowledgment

We thank technologists of the Nishidai Clinic who cooperated for the measurement of the CR value. We also thank laboratory technicians of the Department of Pathology of Saiseikai Central Hospital for supporting the immunohistochemical study.

### References

- Martin B, Paesmans M, Mascaux C, Berghmans T, Lohaire P, Meert A, et al. Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. *Br J Cancer* 2004;91:2018–25
- Au NH, Cheang M, Huntsman DG, Yorlida E, Coldman A, Elliott WM, et al. Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. *J Pathol* 2004;204:101–9
- Saitoh G, Sugio K, Ishida T, Sugimachi K. Prognostic significance of p21waf1, cyclin D1 and retinoblastoma expression detected by immunohistochemistry in non-small cell lung cancer. *Oncol Rep* 2001;8:737–43
- Jin M, Inoue S, Umemura T, Moriya J, Arakawa M, Nagashima K, et al. Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II. *Lung Cancer* 2001;34:207–18.
- Oshita F, Ito H, Ikehara M, Ohgane N, Hamanaka N, Nakayama H, et al. Prognostic impact of survivin, cyclin D1, integrin beta1, and VEGF in patients with small adenocarcinoma of stage I lung cancer. *Am J Clin Oncol* 2004; 27:425–8.
- Mitsudomi T, Hamajima N, Ogawa M, Takahashi T. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. *Clin Cancer Res* 2000;6:4055–63.
- Sasaki M, Sugio K, Kuwabara Y, Koga H, Nakagawa M, Chen T, et al. Alterations of tumor suppressor genes (Rb, p16, p27 and p53) and an increased FDG uptake in lung cancer. *Ann Nucl Med* 2003;17:189–96.
- Gould MK, Maclean CC, Kuschner WG, Ryzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. *JAMA* 2001;285:914–24.
- Marom EM, Sarvis S, Herndon JE II, Patz EF Jr. T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET. *Radiology* 2002; 223:453–9.
- Nomori H, Watanabe K, Ohtsuka T, Naruke T, Suemasu K, Uno K. The size of metastatic foci and lymph nodes yielding false-negative and false-positive lymph node staging with positron emission tomography in patients with lung cancer. *J Thorac Cardiovasc Surg* 2004;127:1087–92.
- Ahuja V, Coleman RE, Herndon J, Patz EF Jr. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with non-small cell lung carcinoma. *Cancer* 1998;83:918–24.
- Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, Verbeke EK, Deneffe GJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. *Leuven Lung Cancer Group. J Clin Oncol* 1999;17:3201–6.
- Higashi K, Ueda Y, Yagishita M, Arisaka Y, Sakurai A, Oguchi M, et al. FDG PET measurement of the proliferative potential of non-small cell lung cancer. *J Nucl Med* 2000;41:85–92.
- Vesselle H, Schmidt RA, Pugsley JM, Li M, Kohlmyer SG, Vallieres E, et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. *Clin Cancer Res* 2000;6:3837–44.
- Nomori H, Watanabe K, Ohtsuka T, Naruke T, Suemasu K, Kobayashi T, et al. Fluorine 18-tagged fluorodeoxyglucose positron emission tomographic scanning to predict lymph node metastasis, invasiveness, or both, in clinical T1 N0 M0 lung adenocarcinoma. *J Thorac Cardiovasc Surg* 2004;128: 396–401.
- Nomori H, Watanabe K, Ohtsuka T, Naruke T, Suemasu K, Uno K. Evaluation of F-18 fluorodeoxyglucose (FDG) PET scanning for pulmonary nodules less than 3 cm in diameter, with special reference to the CT images. *Lung Cancer* 2004;45:19–27.
- Cremerius U, Fabry U, Neuerburg J, Zimny M, Osieka R, Buell U. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. *Nucl Med Commun* 1998;19:1055–63.
- Menda Y, Bushnell DL, Madsen MT, McLaughlin K, Kahn D, Kernstine KH. Evaluation of various corrections to the standardized uptake value for diagnosis of pulmonary malignancy. *Nucl Med Commun* 2001;22:1077–81.
- Nomori H, Watanabe K, Ohtsuka T, Naruke T, Suemasu K, Uno K. Visual and semiquantitative analyses for F-18 fluorodeoxyglucose PET scanning in pulmonary nodules 1 cm to 3 cm in size. *Ann Thorac Surg* 2005;79:984–88; discussion 989.
- Sobin LW, Wittekind CH. UICC TNM classification of malignant tumours. 6th edn. New York: Wiley-Liss 2002;131–41.
- Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. *Stat Med* 1993;12:1293–316.
- Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. *Mod Pathol* 1998;11: 155–68.
- Kim CK, Gupta NC, Chandramouli B, Alavi A. Standardized uptake values of FDG: body surface area correction is preferable to body weight correction. *J Nucl Med* 1994;35:164–7.
- Lindholm P, Minn H, Leskinen-Kallio S, Bergman J, Ruotsalainen U, Joensuu H. Influence of the blood glucose concentration on FDG uptake in cancer—a PET study. *J Nucl Med* 1993;34:1–6.

25. Hamberg LM, Hunter GJ, Alpert NM, Choi NC, Babich JW, Fischman AJ. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? *J Nucl Med* 1994;35:1308-12.
26. Dewan NA, Gupta NC, Redepenning LS, Phalen JJ, Frick MP. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management. *Chest* 1993;104:997-1002.
27. Gupta NC, Maloof J, Gunel E. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. *J Nucl Med* 1996;37:943-8.
28. Imdahl A, Jenkner S, Brink I, Nitzsche E, Stoelben E, Moser E, et al. Validation of FDG positron emission tomography for differentiation of unknown pulmonary lesions. *Eur J Cardiothorac Surg* 2001;20:324-9.
29. Lowe VJ, Fletcher JW, Gobar L, Lawson M, Kirchner P, Valk P, et al. Prospective investigation of positron emission tomography in lung nodules. *J Clin Oncol* 1998;16:1075-84.
30. Nomori H, Ohtsuka T, Naruke T, Suemasu K. Histogram analysis of computed tomography numbers of clinical T1N0M0 lung adenocarcinoma with special reference to lymph node metastasis and tumor invasiveness. *J Thorac Cardiovasc Surg* 2003;126:1584-9.
31. Asamura H, Nakayama H, Kondo H, Tsuchiya R, Shimosato Y, Naruke T. Lymph node involvement, recurrence, and prognosis in resected small, peripheral, non-small-cell lung carcinomas: are these carcinomas candidates for video-assisted lobectomy? *J Thorac Cardiovasc Surg* 1996;111:1125-34.
32. Depierre A, Milleron B, Moro-Sibilot D, Chevret S, Quoix E, Lebeau B, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. *J Clin Oncol* 2002;20:247-53.

# Prognostic Significance of [<sup>18</sup>F]Fluorodeoxyglucose Uptake on Positron Emission Tomography in Patients With Pathologic Stage I Lung Adenocarcinoma

Takashi Ohtsuka, MD, PhD<sup>1</sup>  
 Hiroaki Nomori, MD, PhD<sup>2</sup>  
 Ken-ichi Watanabe, MD<sup>1</sup>  
 Masahiro Kaji, MD, PhD<sup>1</sup>  
 Tsuguo Naruke, MD, PhD<sup>1</sup>  
 Keiichi Suemasu, MD, PhD<sup>1</sup>  
 Kimiichi Uno, MD, PhD<sup>3</sup>

<sup>1</sup> Department of Thoracic Surgery, Saiseikai Central Hospital, Tokyo, Japan.

<sup>2</sup> Department of Thoracic Surgery, Graduate School of Medicine, Kumamoto University, Kumamoto, Japan.

<sup>3</sup> Nishidai Clinic, Tokyo, Japan.

Address for reprints: Hiroaki Nomori, MD, Department of Thoracic Surgery, Graduate School of Medicine, Kumamoto University, 1-1-1 Honjo, Kumamoto 860-8556, Japan; Fax: (011) 81-96-373-5532; E-mail: hnomori@qk9.so-net.ne.jp

Received May 26, 2006; revision received August 11, 2006; accepted August 21, 2006.

**BACKGROUND.** [<sup>18</sup>F]Fluoro-2-deoxyglucose uptake on positron emission tomography (FDG-PET) has been frequently used for diagnosis and staging of lung cancer. The prognostic significance of FDG uptake on PET was evaluated in patients with pathologic Stage I lung adenocarcinoma (tumor stages were based on the TNM classification of the International Union Against Cancer).

**METHODS.** Disease-free survival of 98 patients with pathologic Stage I lung adenocarcinoma who were treated by curative resection was examined in relation to sex, age, histologic grade of differentiation, surgical procedure, tumor stage, and FDG uptake measured as the maximum standardized uptake value (SUV).

**RESULTS.** Sixty-three patients were had Stage IA disease and 35 patients had Stage IB disease. Six patients each with Stage IA and Stage IB disease developed disease recurrence after a mean postsurgical follow-up period of 31 months. Ten (23%) of the 43 patients with SUV  $\geq$  3.3 developed a recurrence compared with 2 (4%) of the 55 patients with SUV  $<$  3.3 ( $P = .020$ ). Ten (20%) of the 51 patients with moderately or poorly differentiated adenocarcinoma developed disease recurrence, compared with 2 (4%) of the 47 patients with well-differentiated adenocarcinoma ( $P = .056$ ). Multivariate analysis demonstrated that histologic grade of differentiation was not correlated with the frequency of tumor recurrence ( $P = .286$ ), whereas SUV was found to be marginally correlated ( $P = .079$ ).

**CONCLUSIONS.** FDG uptake appears to be predictive of disease-free survival in patients with Stage I lung adenocarcinoma. FDG uptake could yield important information for determining the likely value of postoperative adjuvant chemotherapy in such patients. *Cancer* 2006;107:2468-73. © 2006 American Cancer Society.

**KEYWORDS:** lung cancer, positron emission tomography, prognosis, recurrence.

**A**lthough patients with Stage II or Stage III nonsmall cell lung cancer (NSCLC) can generally be considered candidates for postoperative chemotherapy, it is still difficult to determine whether it would be useful for patients with Stage I after complete resection. To determine the potential usefulness of postoperative adjuvant chemotherapy in patients with Stage I NSCLC, it is important to clarify the prognostic factors in these patients.

In recent years, [<sup>18</sup>F]fluoro-2-deoxyglucose uptake on positron emission tomography (FDG-PET) has been used frequently for diagnosis and staging of lung cancer.<sup>1-3</sup> It has also been reported that FDG uptake on PET can be a prognostic factor in patients with NSCLC.<sup>4,5</sup> However, FDG uptake is dependent on the histologic cell type of NSCLC (i.e., FDG uptake by adenocarcinoma is correlated with pathologic tumor stage and tumor invasiveness, whereas that of other histologic types is not).<sup>6,7</sup> We considered that the prognostic

**TABLE 1**  
Patient Characteristics and Number of Patients With Recurred Patients

	No. of patients	No. of recurred patients	Hazards ratio (95% CI)	P
Sex				
Male	56	9		
Female	42	3	0.40 (0.11-1.48)	.169
Age, y				
≥60	64	7		
<60	34	5	0.99 (0.22-2.12)	.949
Histologic grade of differentiation				
Well	47	2		
Moderately	39	6	4.39 (0.96-20.09)	.057*
Poorly	12	4		
Surgery				
Pneumonectomy	1	1		
Lobectomy	80	9	0.97 (0.21-4.51)	.970 <sup>†</sup>
Segmentectomy	17	2		
Pathologic stage <sup>‡</sup>				
IA	63	6		
IB	35	6	0.67 (0.22-2.11)	.497
SUV				
≥3.3	43	10		
<3.3	55	2	6.05 (1.32-27.65)	.020

95% CI indicates 95% confidence interval; SUV, standardized uptake value.

\* P value was calculated between the well-differentiated adenocarcinoma and the moderately or poorly differentiated one.

† P value was calculated between the pneumonectomy or lobectomy group and segmentectomy group.

‡ Tumor stages were based on the TNM classification of the International Union Against Cancer.

significance of FDG uptake should be examined in adenocarcinomas, but not in NSCLC including all histologic types. Therefore, in the current study, we examined the prognostic significance of FDG uptake in patients with pathologic Stage I lung adenocarcinoma.

## MATERIALS AND METHODS

Between December 2001 and January 2005, FDG-PET was performed on 377 patients with pulmonary tumors. Of these patients, 232 had NSCLC and underwent surgery. Of these 232 patients, 109 had pathologic Stage I disease. We excluded 6 patients whose tumors measured <1 cm in greatest dimension because the spatial resolution of the PET scanner is 0.7 to 0.8 cm, making it difficult to image pulmonary nodules that are <1 cm in size.<sup>6</sup> We also excluded 4 patients with squamous cell carcinoma and 1 patient with carcinosarcoma. There was no patient with bronchioloalveolar cell carcinoma. As a result, 98 patients with pathologic Stage I adenocarcinoma who underwent FDG-PET scanning followed by major pulmonary resection with systematic lymph node dissection were eligible to participate in this study (Table 1). The medical records of each patient were examined with regard to sex, age,

operative procedure, tumor stage (Stage IA or Stage IB), and histologic grade of differentiation. The tumor stages were based on the TNM classification of the International Union Against Cancer.<sup>8</sup> Patients were excluded if they had undergone any chemotherapy or radiotherapy before PET scanning. The histologic grade was classified as well, moderately, or poorly differentiated.

## PET Data Analysis

The FDG-PET data were evaluated semiquantitatively on the basis of maximum standardized uptake value (SUV). To measure the maximum SUV, a region of interest (ROI) was placed over the tumor after correction for radioactive decay. The maximum activity in the tumor ROI was then calculated as tumor activity/injected dose / body weight.


## Follow-up and Assessment of Tumor Recurrence

Patients were followed for cancer recurrence. Follow-up data were obtained every 3 months for the first 2 years and every 6 months thereafter. Chest and abdominal computed tomography (CT) scans were performed every 6 months. Each follow-up visit was supplemented by chest radiography, serum biochemistry, tumor marker assay, and any other test required to examine suspected tumor recurrence. In addition, if patients became symptomatic or demonstrated abnormal laboratory findings, appropriate testing (i.e., brain CT and bone scintigraphy) was performed as well. Recurrence was defined as any unequivocal occurrence of new cancer foci in a disease-free patient.

## Statistical Analysis

Receiver operating characteristic (ROC) curves of SUV for the prediction of recurrence were generated using MedCalc (Medisoftware, Mariakerke, Belgium) by plotting sensitivity versus 1-specificity for varying thresholds of SUV. The best combination between sensitivity and specificity was found. Patients with disease recurrence who exceeded the SUV threshold were defined as true-positive and patients without disease recurrence whose SUVs were less than this were defined as true-negative. Patients with disease recurrence whose SUVs were below the threshold were defined as false-negative, and patients without disease recurrence who exceeded the SUV threshold were defined as false-positive. Sensitivity was calculated as true-positive / true-positive + false-negative, and specificity was calculated as true-negative / true-negative + false-positive. The ROC curve was used to determine the cutoff value that yielded the optimal sensitivity and specificity.

The duration of disease-free survival was measured from the date of surgery until the first evidence of disease recurrence or the last date of follow-up for



**FIGURE 1.** The receiver operating characteristic (ROC) curve of the standardized uptake value (SUV) for the prediction of recurrence. Cutoff values for SUV are shown in italics.


patients who remained alive and free of disease. The disease-free interval was analyzed according to the Kaplan-Meier method, and the differences in disease-free survival were assessed by using the log-rank test. Univariate and multivariate analyses (Cox proportional hazards model) were performed to determine independent prognostic predictors.<sup>9</sup> All variables with  $P < .1$  in the univariate analysis were entered in the multivariate analysis. Differences at  $P < .05$  were defined as being statistically significant.

**RESULTS**


**Disease-Free Survival and Univariate Analysis**

The median follow-up period after surgery in the 98 patients was 31 months (range, 14–50 months). There was no surgical death or loss to follow-up. Twelve patients (i.e., 6 patients each with Stage IA and Stage IB disease) developed disease recurrence after surgery. The ROC curve showed that the optimal cutoff value for predicting recurrence was 3.3 (area under the curve, 0.784; standard error of 0.081) (Fig. 1). Using an SUV of 3.3 yielded a sensitivity of 0.917 and a sensitivity of 0.628, a positive predictive value of 0.256, and a negative predictive value of 0.982. The distribution of mean SUV was 3.81 and the standard deviation was 3.75 (range, 0.87–26.2).

Table 1 shows the patient characteristics including sex, age (age  $\geq 60$  years or age  $< 60$  years), histologic grade of differentiation (well, moderately, or poorly dif-



**FIGURE 2.** Disease-free survival of the 98 patients with pathologic Stage I adenocarcinoma according to the standardized uptake value (SUV) of the primary tumor.




**FIGURE 3.** Disease-free survival of the 98 patients with pathologic Stage I adenocarcinoma according to the histologic grade of differentiation. Mod/poor indicates moderately/poorly differentiated.


ferentiated), surgical procedure (pneumonectomy, lobectomy, or segmentectomy), and SUV ( $\geq 3.3$  or  $< 3.3$ ) and results of  $P$  value and hazard ratio by univariate analysis. Sixty-four patients were age  $\geq 60$  years and 34 were age  $< 60$  years. There were 56 male and 42 female patients. Surgical procedures included pneumonectomy in 1 patient, lobectomy in 80 patients, and segmentectomy in 17 patients. Histologically, the tumors were well differentiated in 47 patients, moderately differentiated in 39 patients, and poorly differentiated in 12 patients. Sixty-three patients had Stage IA disease and 35 had Stage IB disease. Forty-three patients had tumors with an SUV  $\geq 3.3$  and 55 patients had an SUV  $< 3.3$ .

As shown in Figure 2, there was a significant difference in disease-free survival between the those patients with an SUV  $\geq 3.3$  and those with an SUV  $< 3.3$  ( $P = .008$ ). A significant difference was also noted





**FIGURE 4.** Disease-free survival of the 63 patients with pathologic Stage IA adenocarcinoma according to the standardized uptake value (SUV) of the primary tumor.



**FIGURE 5.** Disease-free survival of the 35 patients with pathologic Stage IB adenocarcinoma according to the standardized uptake value (SUV) of the primary tumor.

between moderately or poorly differentiated adenocarcinomas and well-differentiated adenocarcinomas (Fig. 3) ( $P = .036$ ). For both Stage IA and IB disease, patients with an SUV  $\geq 3.3$  demonstrated more frequent disease recurrence than those with an SUV  $< 3.3$  (Stage IA,  $P = .024$  and Stage IB,  $P < .001$ ) (Figs. 4 and 5).

Seventeen (27%) of the 63 patients with Stage IA disease and 26 (74%) of the 35 patients with Stage IB disease had tumors with an SUV  $\geq 3.3$  (Table 2). Among the 12 patients with disease recurrence, 4 (67%) of the 6 patients with Stage IA disease and all (100%) of the 6 patients with Stage IB disease had tumors with an SUV  $\geq 3.3$  (Table 3). None of the 9 patients with Stage IB disease who had an SUV  $< 3.3$  (see Table 2) developed disease recurrence.

**TABLE 2**  
Correlation between Pathologic Stage and FDG Uptake Measured by SUV

Stage*	No. of patients	SUV $\geq 3.3$	SUV $< 3.3$
IA	63	17	46
IB	35	26	9
Total	98	44	54

FDG indicates [ $^{18}\text{F}$ ]fluoro-2-deoxyglucose; SUV, standardized uptake value.

\* Tumor stages were based on the TNM classification of the International Union Against Cancer.

**TABLE 3**  
Correlation between Number of Patients With Recurrence and FDG Uptake Measured by SUV

Stage*	No. of recurrence	SUV $\geq 3.3$	SUV $< 3.3$
IA	6	4	2
IB	6	6	0
Total	12	11	1

FDG indicates [ $^{18}\text{F}$ ]fluoro-2-deoxyglucose; SUV, standardized uptake value.

\* Tumor stages were based on the TNM classification of the International Union Against Cancer.

**TABLE 4**  
Multivariate Analysis of Variables for Predicting Disease-Free Survival

Variables	Hazards ratio	95% CI	P
SUV ( $\geq 3.3$ or $< 3.3$ )	4.2	0.8-21.5	.079
Histologic grade of differentiation (well or moderately/poorly)	2.4	0.5-12.2	.286

95% CI indicates 95% confidence interval; SUV, standardized uptake value.

Univariate analysis showed that patients with an SUV  $\geq 3.3$  and moderately or poorly differentiated adenocarcinomas demonstrated more frequent disease recurrence compared with those with an SUV  $< 3.3$  and well-differentiated tumors ( $P = .020$  and  $P = .056$ , respectively) (Table 1). Both of the patients with recurrence of well-differentiated adenocarcinoma (shown in Table 1) had an SUV  $\geq 3.3$ . There were no significant correlations noted between disease recurrence and other variables including sex, age, surgical procedure, and pathologic stage.

**Multivariate Analysis**

Multivariate analysis showed that although SUV with a cutoff value of 3.3 did not achieve statistical significance, it was able to predict tumor recurrence well ( $P = .079$ ) (Table 4). Histologic grade of cell differentiation was found to have no correlation with tumor recurrence ( $P = .286$ ).

## DISCUSSION

Although TNM staging is the most important prognostic factor in patients with NSCLC, it is well known that approximately 30% of patients with Stage I disease die due to disease recurrence within 5 years after surgery.<sup>10,11</sup> Although some studies have shown that postoperative adjuvant chemotherapy can increase survival in NSCLC patients with Stage IB or Stage II disease,<sup>12-14</sup> to our knowledge it has been unclear which population would benefit most from adjuvant chemotherapy. In addition, to our knowledge there have been no data to indicate the value of adjuvant chemotherapy for patients with pathologic Stage IA NSCLC.

We recently reported that clinical Stage IA lung adenocarcinomas with high FDG uptake had more frequent lymph node metastasis, higher tumor invasiveness, and proliferative activity as determined by Ki-67 staining than those with low FDG uptake.<sup>15</sup> The present study also revealed that patients with adenocarcinomas showing an SUV  $\geq$  3.3 had poorer disease-free survival than those with an SUV  $<$  3.3, for patients with both Stage IA and Stage IB disease. Although further research will be needed to define the usefulness of adjuvant chemotherapy for patients with pathologic Stage I disease, our data suggest that patients with pathologic Stage I disease with an SUV  $\geq$  3.3 could be candidates for adjuvant chemotherapy. We also found that none of 9 patients with Stage IB disease demonstrating an SUV  $<$  3.3 developed disease recurrence. Although several studies have reported the benefit of adjuvant treatment for Stage IB NSCLC,<sup>12-14</sup> it appears that we should refer to SUV before administering adjuvant chemotherapy for patients with Stage IB lung adenocarcinoma.

Although the results of the current study demonstrated that the SUV cutoff value for predicting tumor recurrence was 3.3, Cerfolio et al.<sup>4</sup> and Vansteenkiste et al.<sup>5</sup> reported it to be 10 and 7, respectively. The difference between our result and theirs can be explained as follows: 1) the previous 2 reports examined NSCLC patients with Stage I-IV disease, including patients who were not considered candidates for surgical treatment, but we examined only patients with pathologic Stage I disease who were treated by complete resection and mediastinal lymph node dissection; and 2) the previous 2 reports examined patients with all histologic types of NSCLC, but the present study was limited to adenocarcinoma. Because it is reasonable that patients with advanced disease would have a higher SUV and poorer prognosis than those with early-stage disease, SUV could be concluded to be an important prognostic factor when examining patients with Stage I-IV disease. Cerfolio et al.<sup>4</sup> analyzed their own data in detail and reported that NSCLC patients with an

SUV  $\geq$  10 had a higher frequency of disease recurrence than those with an SUV  $<$  10 for Stage IB and Stage II disease, whereas this difference was not significant for patients with Stage IA disease. In addition, it has been reported that the relation between FDG uptake and tumor aggressiveness is significant in adenocarcinoma, but not in other histologic types of NSCLC.<sup>3,6,7</sup> Therefore, we examined the prognostic significance of SUV to determine the potential value of postoperative adjuvant treatment for patients with Stage IA and Stage IB adenocarcinoma, and found that the cutoff value was 3.3.

It has been reported that patients with well-differentiated adenocarcinoma generally have a better postoperative prognosis than those with moderately or poorly differentiated adenocarcinoma at pathologic Stage IA.<sup>16</sup> Although the current study also yielded similar results, the prognostic importance of histologic grade of differentiation was found not to be significant in multivariate analysis. In fact, both patients who developed disease recurrence of well-differentiated adenocarcinoma had tumors with an SUV  $\geq$  3.3. Our results demonstrated that the maximum SUV could be a more reliable factor for predicting recurrence than histologic grade of differentiation in patients with pathologic Stage I adenocarcinoma. However, it should be kept in mind that the small number of enrolled patients is a major limitation of this study, especially for multivariate analysis.

We conclude that FDG uptake measured by maximum SUV has potential value as an independent prognostic factor in patients with Stage I lung adenocarcinoma after surgery, and therefore could yield important information for determining the usefulness of adjuvant chemotherapy in such patients.

## REFERENCES

- Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. *JAMA*. 2001;285:914-924.
- Marom EM, Sarvis S, Hemdon JE 2nd, Patz EF Jr. T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET. *Radiology*. 2002;223:453-459.
- Nomori H, Watanabe K, Ohtsuka T, et al. Fluorine 18-tagged fluorodeoxyglucose positron emission tomographic scanning to predict lymph node metastasis, invasiveness, or both, in clinical T1 N0 M0 lung adenocarcinoma. *J Thorac Cardiovasc Surg*. 2004;128:396-401.
- Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. *J Thorac Cardiovasc Surg*. 2005;130:151-159.
- Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. *J Clin Oncol*. 1999;17:3201-3206.

6. Nomori H, Watanabe K, Ohtsuka T, Naruke T, Suemasu K, Uno K. Evaluation of F-18 fluorodeoxyglucose (FDG) PET scanning for pulmonary nodules less than 3 cm in diameter, with special reference to the CT images. *Lung Cancer*. 2004; 45:19-27.
7. Sagawa M, Higashi K, Sugita M, et al. Fluorodeoxyglucose uptake correlates with the growth pattern of small peripheral pulmonary adenocarcinoma. *Surg Today*. 2006;36:230-234.
8. Sobin LH, Wittekind C, editors. TNM classification of Malignant Tumors. 6th ed. New York: John Wiley & Sons; 2002.
9. Cox D. Regression models and life-tables. *J R Stat Soc*. 1972; 34:187-220.
10. Ohtsuka T, Nomori H, Horio H, Naruke T, Suemasu K. Is major pulmonary resection by video-assisted thoracic surgery an adequate procedure in clinical stage I lung cancer? *Chest*. 2004;125:1742-1746.
11. Pairolero PC, Williams DE, Bergstralh EJ, Piehler JM, Bernatz PE, Payne WS. Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. *Ann Thorac Surg*. 1984;38:331-338.
12. Johnson BE, Rabin MS. Patient subsets benefiting from adjuvant therapy following surgical resection of non-small cell lung cancer. *Clin Cancer Res*. 2005;11:5022s-5026s.
13. Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. *N Engl J Med*. 2004;350:1713-1721.
14. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. *N Engl J Med*. 2005;352:2589-2597.
15. Watanabe K, Nomori H, Ohtsuka T, et al. [F-18]Fluorodeoxyglucose positron emission tomography can predict pathological tumor stage and proliferative activity determined by Ki-67 in clinical stage IA lung adenocarcinomas. *Jpn J Clin Oncol*. 2006.
16. Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. *Cancer*. 1995;75:2844-2852.

## Characteristics of Advantages of Positron Emission Tomography over Computed Tomography for N-staging in Lung Cancer Patients

Akinori Ebihara<sup>1</sup>, Hiroaki Nomori<sup>2,3</sup>, Kenichi Watanabe<sup>2</sup>, Takashi Ohtsuka<sup>2</sup>, Tsuguo Naruke<sup>2</sup>, Kimiichi Uno<sup>4</sup>, Ichiro Kuwahira<sup>5</sup> and Kenji Eguchi<sup>5</sup>

<sup>1</sup>Department of Internal Medicine, Saiseikai Central Hospital, Tokyo, <sup>2</sup>Department of Thoracic Surgery, Saiseikai Central Hospital, Tokyo, <sup>3</sup>Department of Thoracic Surgery, Graduate School of Medical and Pharmaceutical Sciences, Kumamoto University, Kumamoto, <sup>4</sup>Nishidai Clinic, Tokyo and <sup>5</sup>Department of Internal Medicine, Tokai University School of Medicine, Isehara, Kanagawa, Japan

Received March 2, 2006; accepted July 16, 2006; published online October 26, 2006

**Objective:** We analyzed the characteristics of advantages of positron emission tomography (PET) over computed tomography (CT) for N-staging in lung cancer patients.

**Methods:** Preoperative PET and CT scans were performed for 2057 lymph node stations in 205 patients with peripheral-type lung cancer. The advantages of PET over CT for N-staging were analyzed among lymph node locations and histological subtypes.

**Results:** The pathological N-stages were N0 in 143 patients, N1 in 31, N2 in 24 and N3 in 7. PET was able to diagnose N0, N2 and N3 diseases more accurately than CT ( $P = 0.03$ ,  $0.01$  and  $0.02$ , respectively), but there was no significant difference between the two modalities for N1 disease. In the upper mediastinal lymph node stations, both false-negative and false-positive were significantly less frequent with PET than with CT ( $P = 0.001$ ). In the lower mediastinal and supra clavicle lymph nodes, PET showed a lower frequency of false-negative than CT ( $P = 0.04$  and  $0.003$ , respectively), but there was no significant difference in the frequency of false-positive between the two modalities. Among histological types, PET could stage adenocarcinoma with less frequent false-negative and squamous cell carcinoma with less frequent false-positive than CT ( $P = 0.02$  and  $0.005$ , respectively).

**Conclusion:** For N-staging, PET was superior to CT for the following: (1) more accurate for N0, N2 and N3 diseases but not for N1; (2) lower frequency of false-positive in the upper mediastinal nodes; and (3) lower frequencies of false-negative in adenocarcinoma and false-positive in squamous cell carcinoma. Recognizing these advantages of PET could make the N-staging of lung cancer more accurate.

*Key words:* positron emission tomography – computed tomography – lymph node stage – lung cancer – adenocarcinoma

### INTRODUCTION

CT scanning has been a usual procedure of N-staging of lung cancer. However, CT scanning is not sufficiently sensitive or specific for diagnosing lymph node metastasis, because size is the only criterion used to differentiate benign from malignant lymph nodes (1). In recent years, <sup>18</sup>F-fluorodeoxyglucose (FDG)-PET scanning has been used for the staging of lung cancer (2–7). Because of the

biological nature of FDG, FDG-PET has been reported to be able to detect metastatic lymph nodes more accurately than CT. A meta-analysis by Dwamena et al. of PET scanning of 514 patients in 14 studies showed that the mean sensitivity and specificity of PET scanning for N-staging were 0.79 (range: 0.62–0.97) and 0.91 (range: 0.79–0.99), respectively, both being superior to those of CT scanning, i.e. 0.60 (range: 0.25–0.89) and 0.77 (range: 0.44–0.95) (1). However, the advantages of PET over CT for lymph node staging of lung cancers have not been fully characterized. In this study we examined the characteristics of advantages of PET over CT for lymph node staging, especially among various lymph node locations and histological types.

For reprints and all correspondence: Hiroaki Nomori, Department of Thoracic Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1, Honjo, Kumamoto 860-8556, Japan. E-mail: hnomori@kaiju.medic.kumamoto-u.ac.jp